Discovery of Fisetin as a potent and cell-active ACVR2A inhibitor.
Key claim: Fisetin is a potent small-molecule ACVR2A inhibitor that suppresses TGF-β/Smad signaling and protects C2C12 myotubes from Activin A-induced atrophy, positioning it as a lead for muscle-preserving anti-obesity therapy.
Abstract
Current weight-loss drugs, such as GLP-1 receptor agonists, are effective at reducing body weight but are often associated with concomitant loss of muscle mass. Thus, there is growing interest in developing next-generation anti-obesity agents that preserve muscle tissue. ACVR2A has emerged as a promising target in this context, as its inhibition may uncouple fat loss from muscle wasting. While several anti-ACVR2A monoclonal antibodies have advanced into clinical trials, small-molecule inhibitors remain scarcely reported. In this study, virtual screening followed by experimental validation was employed to identify the natural product fisetin as a potent ACVR2A inhibitor. Fisetin exhibited robust enzymatic inhibitory activity, with an IC₅₀ value of 0.27 ± 0.06 μM, and demonstrated high binding affinity, with a Kof 0.12 ± 0.03 μM. Cellular assays further confirmed that fisetin suppressed TGF-β/Smad signaling and successfully protected C2C12 myotubes from Activin A-induced atrophy by downregulating atrogenes. Despite its favorable in vitro profile, fisetin showed poor pharmacokinetic properties that currently limit its in vivo application; therefore, preliminary structural modifications were explored to guide future optimization. Collectively, these findings position fisetin as a promising lead compound for the development of ACVR2A-targeted therapies aimed at combating obesity while preserving muscle mass.
Why this matters
The muscle-loss liability of GLP-1-class AOMs has become the dominant trend-adjacent concern in longevity-clinic marketing, and ACVR2A/activin blockade (bimagrumab, etc.) is already being pitched as the pharmacological fix. A repurposing claim that an over-the-counter senolytic flavonoid hits the same target will travel fast in biohacker channels well ahead of any in-vivo evidence — the divergence between a cell-plate IC50 and a human muscle-preservation outcome is exactly the gap this area exists to flag.